CRISPR Therapeutics
- Market cap
- 5.06B
- P/E (TTM)i
- -11.11
- P/Bi
- 2.90
- EPSi
- -6.47
- Div yieldi
- 0.00%
- 52W posi
- 27%
Anonymous reader poll. Unscientific, not investment advice.
CRISPR Therapeutics shares were changing hands at 52.35, down 3.06% on the day. At current prices, the business is worth about 5.06B, the #2057 most valuable US-listed company we track. Across 12 analysts the consensus rating is Buy, with an average price target of 76.18 (+46%). Against a 52-week band of 44.12-75.16, the shares are currently 27% of the way up.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 1 day.
- Its last 3 Sell calls were followed by a 4% average decline over the next quarter.
- Recent price momentum is -19.9% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 19.7% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 54.00
- Open
- 53.00
- Day range
- 52.27 - 54.59
- Avg price
- 53.17
- Volume
- 1.68M
- Turnover
- 89.34M
- Turnover ratei
- 1.75%
- Volume ratioi
- 1.09
- Amplitudei
- 4.30%
- 52-week rangei
- 44.12 - 75.16
Valuation
- P/Ei
- -8.09
- P/E (TTM)i
- -11.11
- P/Bi
- 2.90
- EPSi
- -6.47
- Book value / shi
- 18.06
- Net profit
- -625.60M
- Net assets
- 1.75B
Share structure
- Market cap
- 5.06B
- Float capi
- 5.04B
- Shares out
- 96.69M
- Float sharesi
- 96.26M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2016-10-19
30.3% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-8.02M net over the window
Short interest
- Shares short
- 19.07M
- % of floati
- 19.72%
- Days to coveri
- 16.54
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of CRISPR Therapeutics (CRSP)?
CRISPR Therapeutics last traded at 52.35. The quote on this page refreshes every few seconds while US markets are open.
What is CRISPR Therapeutics's market cap?
About 5.06B.
What is the P/E ratio of CRISPR Therapeutics?
The trailing twelve-month P/E is -11.11. The Valuation tab shows it against the stock's own five-year range.
Does CRISPR Therapeutics pay a dividend?
CRISPR Therapeutics does not currently pay a regular dividend.
Is CRISPR Therapeutics a buy according to analysts?
The consensus of 12 analysts is a Buy rating, with an average 12-month price target of 76.18, which implies 45.5% upside from the current price. This is not investment advice.
What is CRISPR Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates CRISPR Therapeutics a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-10-08 06:41:25 · For reference only, not investment advice and not tailored to your situation.